GGrantIndex
Sort

17,054 grants matching genome editing

Elucidation of mutant p53-medidated mechanisms in promoting metastatic esophageal cancer

$46,843
Gizem Efe · Columbia University Health Sciences · F31 · FY2023 · CA

Dissecting how gene regulatory redundancy ensures robustness of mammalian development

$46,770
Joshua Andrei Alcantara · University Of California-Irvine · F31 · FY2025 · HD

Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC

$46,752
Bianca Diaz · Weill Medical Coll Of Cornell Univ · F31 · FY2022 · CA

Determining the cell fate programs of mammalian retina development

$46,752
Martin Tran · California Institute Of Technology · F31 · FY2022 · EY

The conserved transcription factor UNC-30/PITX1-3 coordinates synaptogenesis and cell identity in C. elegans motor neurons

$46,752
Edgar Orlando Correa-Colã“n · University Of Chicago · F31 · FY2022 · NS

Defining the role of the nuclear lamina in the mechanical regulation of lung fibrosis

$46,752
Emma Carley · Yale University · F31 · FY2022 · HL

Anti-CRISPR-mediated Acylation and Bioreversible Esterification for Precision Genome Editing

$46,752
Axel O Vera · Massachusetts Institute Of Technology · F31 · FY2022 · GM

Biochemical studies of aberrant chromatin regulation in cancer

$46,752
Nicholas Prescott · Weill Medical Coll Of Cornell Univ · F99 · FY2022 · CA

Characterization of P. falciparum gametocyte-essential genes using a novel genetic screen

$46,752
Sean Taylor Windle · Seattle Children'S Hospital · F31 · FY2022 · AI

Elucidating the RNA-mediated mechanisms governing H3K9me3 deposition in fragile X syndrome

$46,752
Thomas Ernst Malachowski · University Of Pennsylvania · F31 · FY2022 · NS

Understanding the divergent functions of mutant p53

$46,752
Margaret Kennedy · Sloan-Kettering Inst Can Research · F31 · FY2022 · CA

Progeria and Vasculature: Investigating Genetic Effects and the Potential of Genome Editing for Treatment

$46,752
Crystal Kennedy · Duke University · F31 · FY2022 · HL

Dynamics of Mitochondrial Inheritance in C. elegans Primordial Germ Cells

$46,752
Aaron Zachary Schwartz · New York University School Of Medicine · F31 · FY2022 · HD

Defining mechanisms of lipoprotein turnover and their regulation by ASGR1

$46,752
Tabea Moll · Johns Hopkins University · F31 · FY2022 · HL

Role of TREM2 R47H in Alzheimer's disease using novel CRISPR/Cas9 mouse models

$46,735
Paul Ja-Wen Cheng-Hathaway · Case Western Reserve University · F30 · FY2016 · AG

Decoding Alzheimer's disease-related enhancers in microglia

$46,730
Bethany Rose Fixsen · University Of California, San Diego · F30 · FY2021 · AG

Exploiting RNAi-based silencing of Myc and metabolic vulnerabilities to prevent relapse after Kras inhibition in lung cancer

$46,691
Ankur Sheel · Univ Of Massachusetts Med Sch Worcester · F30 · FY2019 · CA

Genome Engineered Natural Killer Cell Immunotherapy against Human Osteosarcoma

$46,683
Gabrielle Matilde Robbins · University Of Minnesota · F30 · FY2024 · OD

Nanoparticle delivery of triplex-forming PNAs for thalassemia gene therapy

$46,590
Nicole McNeer · Yale University · F30 · FY2011 · HL

Genetic Technology Fabrication and Development Core

$46,567
David L Van Vactor · Harvard Medical School · P01 · FY2020 · NS

Leveraging Tissue-Specific Regulatory Grammar to Interpret Human Evolution and Non-coding Variation

$46,114
Steven K. Reilly · Harvard University · F32 · FY2019 · HG

Uncovering the Role of the MS4A Gene Family in Alzheimer's Disease

$46,094
Alexandra Munch · Icahn School Of Medicine At Mount Sinai · F31 · FY2023 · AG

Functional Role for H3 Serotonylation During Critical Periods of Postnatal Brain Development and Plasticity

$46,094
Ashley Cunningham · Icahn School Of Medicine At Mount Sinai · F31 · FY2023 · NS

Functional and Transcriptional Mechanisms of Familial Brugada Syndrome

$46,073
Kevin R. Bersell · Vanderbilt University · F30 · FY2017 · HL

Alzheimer's Disease Genetic Risk and Microglial Innate Immune Memory

$46,060
Zena Chatila · Columbia University Health Sciences · F30 · FY2021 · AG